Cognition Therapeutics (CGTX) Current Assets (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Current Assets of $35.8 million for Q1 2026, up 56.63% year-over-year from $22.9 million in Q1 2025, and down 25.37% quarter-over-quarter from $48.0 million in Q4 2025.
Cognition Therapeutics (CGTX) Current Assets (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Current Assets for 7 consecutive years, with $35.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 56.63% year-over-year to $35.8 million; the TTM figure through Mar 2026 stood at $35.8 million (up 56.63% YoY), while the FY2025 annual figure was $48.0 million, up 62.38% from the prior year.
- Current Assets declined to $35.8 million in Q1 2026 per CGTX's latest filing, from $48.0 million in the prior quarter.
- Across five years, Current Assets topped out at $56.4 million in Q1 2022 and bottomed at $19.0 million in Q2 2025.
- Historically, Current Assets has averaged $38.6 million across 5 years, with a median of $38.0 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets surged 407.39% — and 2025, when it slumped 43.22%.
- Cognition Therapeutics' Current Assets stood at $47.6 million in 2022, then fell by 28.18% to $34.2 million in 2023, then retreated by 13.64% to $29.6 million in 2024, then jumped by 62.38% to $48.0 million in 2025, then fell by 25.37% to $35.8 million in 2026.
- Business Quant data shows CGTX's Current Assets at $35.8 million in Q1 2026, $48.0 million in Q4 2025, and $42.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 38.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.30 Mn |
| Mar 31, 2026 | 35.81 Mn |
| Dec 31, 2025 | 47.99 Mn |
| Sep 30, 2025 | 42.88 Mn |
| Jun 30, 2025 | 19.05 Mn |
| Mar 31, 2025 | 22.87 Mn |
| Dec 31, 2024 | 29.56 Mn |
| Sep 30, 2024 | 26.83 Mn |
| Jun 30, 2024 | 33.55 Mn |
| Mar 31, 2024 | 37.97 Mn |
| Dec 31, 2023 | 34.22 Mn |
| Sep 30, 2023 | 36.04 Mn |
| Jun 30, 2023 | 41.55 Mn |
| Mar 31, 2023 | 42.80 Mn |
| Dec 31, 2022 | 47.65 Mn |
| Sep 30, 2022 | 50.93 Mn |
| Jun 30, 2022 | 50.74 Mn |
| Mar 31, 2022 | 56.44 Mn |
| Dec 31, 2021 | 58.99 Mn |
| Sep 30, 2021 | 10.04 Mn |